FRAMINGHAM (09/24/2003) - Bio/pharma company Renovis Inc. has raised US$45 million in funding to help it undertake preclinical and clinical trials of its drug candidates. The company focuses on the discovery and development of drugs to treat neurological diseases and disorders. Renovis has a Phase II candidate called REN-1654, which is for neuropathic pain. And later this year, the company will begin enrolling patients for a Phase I study for another drug candidate called REN-213, which is for patients with post-operative pain. The company also has a Phase III drug candidate for acute ischemic stroke called Cerovive, which is licensed to AstraZeneca PLC.
- Free Whitepaper! Learn how to create an analytics environment that is governed, scalable and self-serve.
- Free Whitepaper! The 5 criteria to help you select the right analytics platform for your organization.
- Free Whitepaper! Learn how IT is evolving from producer to enabler, and fostering collaboration around analytics.